Myriad Genetics (MYGN) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Myriad Genetics (MYGN) has outperformed Intellia Therapeutics (NTLA) over the past year, losing 45.0% versus a loss of 48.5%. Over five years, MYGN leads with a -86.8% price change compared with -90.3% for NTLA. Intellia Therapeutics is the larger company by market cap ($1.77 billion vs $401.7 million), about 4.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | NTLA |
|---|---|---|
| Share price | $4.20 | $12.60 |
| Market cap | $401.73M | $1.77B |
| 1-day change | -1.87% | +7.60% |
| YTD return | -31.71% | +40.16% |
| 1-year return | -45.03% | -48.51% |
| 5-year return | -86.77% | -90.34% |
| EPS (TTM) | $-1.18 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $67.67M |
| Revenue growth (YoY) | — | +16.92% |
| Net income (latest FY) | — | $-412.69M |
| Operating margin | — | -651.67% |
| Net margin | — | -609.85% |
| 52-week high | $8.59 | $28.25 |
| 52-week low | $2.74 | $7.95 |
| Distance from 52-week high | -51.11% | -55.40% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -6.90% | +83.41% |
| Average volume | 2.02M | 4.26M |
| Shares outstanding | 95.65M | 140.13M |
| Employees | 2,700 | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 4.4 times larger than Myriad Genetics by market value ($1.77B vs $401.73M).
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
MYGN vs NTLA FAQ
Which is bigger, Myriad Genetics or Intellia Therapeutics?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.77B compared with $401.73M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, MYGN or NTLA?
MYGN returned -45.03% over the past 12 months, compared with -48.51% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.